Promedior Innately Superior Therapeutics for Fibrosis
 

About Promedior

Leadership in Fibrosis

Pipeline

News & Events

Careers

Contact Us

See our novel approach to fibrosis

Promedior is a clinical stage biopharmaceutical company developing novel therapeutics for the treatment of fibrosis.

Fibrosis is one of the greatest unmet needs in medicine today. Promedior is pioneering the development of targeted therapeutics to treat fibrotic diseases by regulating the innate immune system response to injury.

Utilizing an entirely new approach, Promedior has developed a proprietary platform of pentraxin therapeutics based upon breakthrough discoveries in how monocyte-derived cells – such as macrophages, fibrocytes and dendritic cells – control the initiation, progression and resolution of fibrosis.

Promedior’s pentraxin therapeutics promote healing of damaged tissue by naturally targeting monocyte-derived cells at the site of injury and directing their differentiation into pro-resolution regulatory macrophages.

 
 

News & Events

Publication
Santhiago MR, et al. (2011) Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits. Experimental Eye Research Sep 14.

November 7, 2011
Promedior Presents Preclinical Data at AASLD Demonstrating That Pentraxin-2 Suppresses Liver Fibrosis and Has a Clear Hepatoprotective Effect

November 2, 2011
Promedior Announces Presentation of Preclinical Data at AASLD Demonstrating that Pentraxin-2 Suppresses Liver Fibrosis

May 16, 2011
Promedior Presents Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2011

May 5, 2011
Promedior to Present Clinical Data for PRM-151 (rhPTX-2) in Idiopathic Pulmonary Fibrosis at ATS 2011

May 4, 2011
Promedior Announces Presentation of Preclinical Data at ARVO Demonstrating PRM-151 (rhPTX-2) Reduces Neovascularization in Retinal Diseases

April 19, 2011
Promedior Announces Presentation of Data at ARVO Demonstrating that PRM-151
(rhPTX-2) Suppresses Choroidal and Retinal Neovascularization

February 10, 2011
Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Pulmonary Fibrosis

February 10, 2011
Promedior Initiates Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in Patients with Idiopathic Pulmonary Fibrosis (IPF)

September 7, 2010
Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Asthma and Asthma-Induced Lung Fibrosis

September 7, 2010
Promedior Announces Initiation of Phase 2a Clinical Study of Anti-Fibrotic Therapeutic, PRM-151, in the Prevention of Post-Surgical Scarring in Glaucoma Patients

March 16, 2010
Promedior Closes $12 Million Series C Financing


 
   
 

design by Digizyme